This page shows the latest momelotinib news and features for those working in and with pharma, biotech and healthcare.
GSK’s New Drug Application (NDA) for momelotinib has been accepted by the US Food and Drug Administration (FDA) for patients who have myelofibrosis with anaemia. ... The FDA is due to make a decision on momelotinib – which GSK maintains may address a
Unification will help to uphold and progress promising Momelotinib treatment which targets myelofibrosis. ... The company’s therapy, Momelotinib, has a differentiated mode of action with inhibitory activity along key signalling pathways.
Gilead has suffered another late-stage pipeline blow, posting lacklustre data for momelotinib – a would-be rival to Incyte/Novartis' blockbuster Jakafi/Jakavi. ... drug. A better profile against anaemia was held up as a key differentiator when Gilead
Behind idelalisib, Gilead has a JAK1/JAK2 inhibitor called momelotinib in phase III testing for myelofibrosis, simtuzumab for pancreatic and colorectal cancer in phase II and GS-5745, an entire MMP9
More from news
Approximately 3 fully matching, plus 1 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...